Patent ID: 7915240

Claim:
A method for treating warm-blooded animals, including humans, suffering from asthma or allergic rhinitis, comprising the administration to a patient in need thereof of an appropriate amount of a pharmaceutical composition comprising at least one immunomodulatory compound of the following general formula (I): Wherein: m and n, independently from each other, are an integer ranging from 1 to 4, X and Y each designate a group either in neutral or charged state, selected from the following groups: carboxyl —COOH, dihydroxyphosphoryloxy —O—P(O) (OH) 2 , hydroxysulfonyloxy —O—SO 2 (OH), amino —NH 2 , hydroxyl —OH, [amino(C 1 -C 10 )alkyl]aminocarbonyl —CONH(CH 2 ) n1 —NH 2 , with n 1 being an integer from 1 to 10, [dicarboxy(C 1 -C 5 )alkyl]aminocarbonyl —CO—NH—CH(COOH)—(CH 2 ) n1 —COOH, with n 1 being an integer from 1 to 5, {carboxy[amino(C 1 -C 5 )alkyl]}aminocarbonyl —CO—NH—CH(COOH)—(CH 2 ) n1 —NH 2 , with n 1 being an integer from 1 to 5, amino(C 1 -C 15 )alkanoyloxy —O—CO—(CH 2 ) n1 —NH 2 , with n 1 being an integer from 1 to 15, dihydroxy (C 1 -C 10 ) alkanoyloxy —O—CO—(CH 2 ) n1 —CHOH—CH 2 OH, with n 1 being an integer from 1 to 10, hydroxy(C 1 -C 10 )alkanoyloxy —O—CO—(CH 2 ) n1 —OH, with n 1 being an integer from 1 to 10, carboxy(C 1 -C 10 )alkanoyloxy —O—CO—(CH 2 ) n1 —COOH, with n 1 being an integer from 1 to 10, oxo(C 1 -C 5 )alkanoyloxy —O—CO—(CH 2 ) n1 —CHO, with n 1 being an integer from 1 to 5, [carboxy(C 1 -C 10 )alkanoyl]amino(C 1 -C 15 )alkanoyloxy —O—CO—(CH 2 ) n1 —NH—CO—(CH 2 ) n2 -COOH, with n 1 being an integer from 1 to 10, and n 2 being an integer from 1 to 15, R 1 and R 2 each designate an acyl group derived from a saturated or unsaturated, straight-or branched-chain carboxylic acid having from 2 to 18 carbon atoms, which is unsubstituted or bears one to three substituents selected among hydroxyl, dihydroxyphosphoryloxy, alkyl of 2 to 18 carbon atoms, alkoxy of 2 to 18 carbon atoms, acyloxy of 2 to 18 carbon atoms in the acyl moiety, amino, acylamino, C *1 and C *2 , independently from each other being asymmetric carbons in configuration R, S, or in the racemic form RS, or a pharmaceutically acceptable salt or solvate thereof, optionally in conjugation or admixture with an inert non-toxic pharmaceutically acceptable diluent or carrier.